DexCom had eight patents in internet of things during Q3 2023. DexCom Inc filed patents in Q3 2023 for methods of presenting glucose level data, remote monitoring of analyte sensors, self-calibration of continuous analyte sensors, power activation modules for wearable electronic components, and a biosensor apparatus with a robotic placement device. These patents aim to improve the accuracy and convenience of glucose monitoring and wearable technology. GlobalData’s report on DexCom gives a 360-degreee view of the company including its patenting strategy. Buy the report here.
DexCom grant share with internet of things as a theme is 38% in Q3 2023. Grant share is based on the ratio of number of grants to total number of patents.
Application: User interfaces for continuous glucose monitoring (Patent ID: US20230260647A1)
The patent filed by DexCom Inc. describes methods for presenting glucose level data and generating alerts based on the glucose level of a patient. The disclosed methods involve accessing the current glucose level of a patient and determining whether certain conditions associated with the alerts are satisfied. The alerts are generated based on the state of the device and the state of the application.
The patent claims provide further details on the methods described. Claim 1 outlines the steps of accessing the current glucose level, accessing conditions associated with the alerts, determining whether the conditions are satisfied, and generating the alerts based on the state of the device and the application. Claim 2 specifies that the state of the device can be locked, unlocked, muted, or unmuted, while the state of the application can be active or inactive. Claim 3 further explains that the application is considered active when it is displayed on the foreground of the device's screen and inactive when it is displayed on the background.
Claims 4 to 8 describe different types of alerts and their corresponding display methods based on the state of the device and the application. For example, claim 4 states that non-audible alerts, such as vibration or visualizations like a flashing or shaded screen, can be used when the device is in a muted state. Claim 5 specifies that local notifications can be displayed on the locked screen of the device, showing an identifier associated with the alerts, as well as the current glucose level and a trend arrow representing the rate of change. Claim 7 mentions the use of banners to display alerts on the device's screen when it is unlocked and the application is inactive.
Claims 9 to 13 introduce additional features, such as re-generating alerts at a predetermined frequency until acknowledgment is received or conditions are no longer satisfied (claim 9), different types of alerts including urgent low, low, high, rise rate, fall rate, or no data alerts (claim 10), and adjusting threshold values associated with the alerts during a predetermined period of time to increase the frequency of satisfying the conditions (claim 12).
The patent also includes a system embodiment, as described in claims 14 to 20. The system comprises a processor and memory configured to execute the application and perform the operations related to generating alerts based on the glucose level and the states of the device and application.
In summary, the patent filed by DexCom Inc. describes methods and systems for presenting glucose level data and generating alerts based on the glucose level of a patient. The alerts are generated based on various conditions and can be displayed in different ways depending on the state of the device and the application.